Marini S, Serata D, Brugnoli R
Didactic-Scientific Board of Master on Clinical Trials, School of Medicine and Psychology, Sapienza University of Rome, Italy.
Clin Ter. 2013 May-Jun;164(3):e211-22. doi: 10.7417/CT.2013.1571.
Monoamine oxidase inhibitors (MAO-I) are the first drugs of antidepressant classes discovered. Phenelzine is a worldwide prescribed MAO-I, studied in a variety of mood and anxiety disorders. Purpose of the present paper is to critically review the results reported in the scientific international literature focusing on efficacy and safety of phenelzine in clinical psychiatric practice, in order to achieve a better understanding of the relationship between pharmacological data, therapeutic approach and side or adverse effects. We performed a careful PubMed (1980-2012) search on clinical pharmacology and clinical use of phenelzine in various psychiatric disorders. We reported our findings discussing separately clinical pharmacology data and systematic controlled, randomised and not randomised, clinical studies.
单胺氧化酶抑制剂(MAO-I)是最早被发现的抗抑郁药物类别。苯乙肼是一种在全球范围内被处方使用的MAO-I,已针对多种情绪和焦虑障碍进行了研究。本文的目的是批判性地回顾国际科学文献中报道的关于苯乙肼在临床精神科实践中的疗效和安全性的结果,以便更好地理解药理学数据、治疗方法与副作用或不良反应之间的关系。我们对PubMed(1980 - 2012年)进行了仔细检索,以查找苯乙肼在各种精神障碍中的临床药理学和临床应用情况。我们报告了我们的研究结果,分别讨论了临床药理学数据以及系统对照、随机和非随机的临床研究。